Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company's product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California.
| Revenue (Most Recent Fiscal Year) | $7.00M |
| Net Income (Most Recent Fiscal Year) | $-56.03M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.77 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -64.42% |
| Return on Assets (Trailing 12 Months) | -54.83% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.52 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.52 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.57 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.99 |
| Earnings per Share (Most Recent Fiscal Year) | $-7.66 |
| Diluted Earnings per Share (Trailing 12 Months) | $-7.66 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 7.37M |
| Free Float | 6.69M |
| Market Capitalization | $54.03M |
| Average Volume (Last 20 Days) | 0.13M |
| Beta (Past 60 Months) | 0.43 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 67.90% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |